An experienced entrepreneur with a strong scientific and operational background, Sue brings a decade of experience in pharmaceutical management and research with Abbott Labs and Eli Lilly & Company and more than 16 years of senior management experience with entrepreneurial firms in Florida including three start-ups. At AGTC, Sue has successfully secured investments of more than $91 million from nationally recognized venture capitalists and granting agencies; negotiated and closed on a major collaboration with a top five Biotech company; lead the company to complete critical milestones; and recruited an experienced management team. Her experience as a group leader with Abbott’s Diagnostic Division helped hone her skills in bringing new products and technologies from the lab bench into the market place.
Sue sits on the board of the University of Florida’s Center for Entrepreneurship, BioFlorida, Southeast BIO, Gainesville Area Innovation Network, and the Florida High Tech Corridor Council. She has a degree in biochemistry from Michigan State University and an MBA from the University of Florida where she was one of the first graduates from the Warrington College of Business Entrepreneurship program.
Steve has more than 15 years of experience as a senior executive in the biotechnology industry. Prior to joining AGTC, he was most recently employed by NeoStem, Inc., a developer of cell-based therapeutics, where Steve served as Executive Vice President and a member of the Board of Directors. He was Senior Vice President of Operations and Corporate Development for Osiris Therapeutics, Inc., where he was part of the senior leadership team that achieved approval of the first-ever stem cell drug therapy, Prochymal®. Steve was also responsible for the launch and overall management of the Bio-Surgery business unit as well as operational oversight for mulitple functional areas including manufacturing, human resources, IT, legal and business development. Prior to Osiris, Steve served as Senior Vice President of Corporate and Business Development at Genzyme Corporation and as Vice President of Corporate and Business Development. Over his ten years at Genzyme, Steve was the senior leader for its global corporate and business development team that provided strategic and transaction support, including support for many of Genyzme's cell therapy opportunities. He has also held positions at DuPont Pharmaceuticals, E.I. Dupont de Nemours and Company, Inc., and Booz Allen & Hamilton. Steve earned a B.S. from University of Massachusetts and an MBA from Harvard Business School.
Dr. Shearman has over 20 years of experience as a senior pharmaceutical executive, with a track record of achievements in drug discovery and development. Prior to joining AGTC, he was employed by EMD Serono, Inc., the U.S. and Canadian subsidiary of Merck KGaA, since 2009 as Senior Vice-President of Research & Early Development. In that role, Dr. Shearman was responsible for discovery research & early development strategy for multiple treatment modalities and played a leadership role in establishing numerous collaborative partnerships. Previously, Dr. Shearman was Executive Director of Merck & Co. Research Laboratories, Boston, where he was Head of the Neuroscience Drug Discovery Department and member of the Core Leadership Team. He also served as Senior Director of the Department of Cellular & Molecular Neuroscience at the Merck Sharp & Dohme Research Laboratories Neuroscience Research Centre, U.K.
Dr. Shearman earned a B.Sc. (Hons) from the University of Bristol, a Ph.D. from the University of Nottingham and conducted academic research at institutes in Japan and Germany. He has also authored more than 110 research publications and book chapters, and has served on numerous editorial, scientific and government advisory panels.
Bill has more than 20 years of experience in corporate finance, leading strategic transactions, fundraising, and accounting. Prior to joining AGTC, he worked at Merrimack Pharmaceuticals Inc. for close to 10 years and held a variety of important leadership positions, including Chief Financial Officer, Principal Accounting Officer and Treasurer. While at Merrimack, he led the company's $100 million initial public offering, helped the company raise more than $400 million in debt and equity capital as a public company, and played a key role in the company’s commercial launch of ONIVYDE® and subsequent asset sale to Ipsen SA for up to $1.025 billion. Prior to his role at Merrimack, Mr. Sullivan held a variety of positions in the areas of financial planning and analysis, operations management, and auditing.
Bill holds a B.A. in Economics from Williams College and a M.B.A and M.S. in Accounting from Northeastern University and obtained his certified public accountant license while working at Arthur Andersen, LLP.
Andrew brings more than 25 years of experience to his role as AGTC’s General Counsel and has extensive experience representing public companies, including multiple IPOs, follow-on financings and acquisition transactions. Most recently, he served as Executive Vice President, Administration, Corporate Secretary and General Counsel for Dyax Corp. until it was acquired by Shire Plc in 2016. During his tenure at Dyax, Andrew managed all legal, compliance and administrative functions during a period of rapid growth in which the company’s market capitalization grew from $180 million to $6 billion. While at Dyax, he also established more than 75 revenue-generating collaborations with biotech and pharma companies in the United States, Europe, India, Australia and Japan. In addition to his legal capabilities, Andrew was also responsible for transforming Dyax’s human resource department and corporate culture, resulting in the company being named to the Boston Globe Top Places to Work in 2013, 2014 and 2015.
Previously, Andrew was a member of the business law practices at Prince Lobel Tye LLP and Nutter, McClennen & Fish LLP. Prior to attending law school, he also served as a Trading Specialist and Senior Analyst of Corporate Listings for the American and New York Stock Exchanges. Andrew holds a B.A. in Finance from the Isenberg School of Management, University of Massachusetts and a J.D. from The George Washington University School of Law.
Dr. Feinsod is a board-certified ophthalmologist with extensive corporate and regulatory expertise in the development of novel therapies for ophthalmic diseases. In his previous positions he has played key roles in corporate finance, developing and implementing clinical and regulatory strategy, due diligence, and licensing. He has been a founder in several companies including Imagen Biotech, a venture-backed company dedicated to developing breakthrough ophthalmology treatments for high unmet needs. At Imagen he secured financing of $40MM from a syndicate of three global investor groups and led all company activities. Prior to Imagen, Dr. Feinsod was SVP of Strategy and Product Development at Eyetech Pharmaceuticals where he spent five years in a variety of functions helping to develop and launch Macugen and an anti-PDGF aptamer now in Phase 3 clinical trials with Ophthotech. Prior to joining Eyetech, Dr. Feinsod served as medical officer for the FDA Division of Anti-inflammatory, Analgesic and Ophthalmologic Drug Products, where he was a primary reviewer for both IND and NDA ophthalmology regulatory applications. Concurrently, he held a clinical trials/drug development fellowship position in George Washington University's Department of Ophthalmology and served on the University hospital's Institutional Review Board. Previously, Dr. Feinsod conducted post-doctoral molecular biology research with a focus on nucleotide science at Cornell University Medical Center.
He received his undergraduate degree from the Wharton School of Business and his MD from the George Washington University School of Medicine and completed his residency at the Manhattan Eye, Ear and Throat Hospital. Dr. Feinsod holds several patents in the field of ophthalmology and in emitted light-stabilization. Dr. Feinsod serves on the board of directors of World Eye Mission, a non-profit organization. He continues to practice ophthalmology on a part-time basis.
Dr. Ozden is responsible for leading the development of pipeline product candidates and overseeing the company's clinical research operations. Dr. Ozden was employed most recently by GlaxoSmithKline plc., where she served as Vice President and Head of Clinical Ophthalmology since May 2014. Previously, she was Executive Medical Director of Ophthalmology at Quark Pharmaceuticals, Inc. from 2011 to 2014. Dr. Ozden served in the Clinical Affairs Department at Bausch & Lomb Pharmaceuticals and also held positions with increasing responsibilities in the Clinical and Regulatory Affairs Department at Carl Zeiss Meditec, Inc. Dr. Ozden earned a doctor of medicine degree from the Hacettepe University School of Medicine in Ankara, Turkey, and after finishing an ophthalmology residency in Turkey she completed clinical glaucoma fellowship training at the New York Eye and Ear Infirmary.
Dr. Chulay brings broad medical and regulatory expertise to AGTC. Since joining the company in 2007, he has achieved Investigational New Drug submissions and strong clinical trial results for the Alpha 1 Antitrypsin Deficiency and Leber Congenital Amaurosis programs.
Prior to joining AGTC, Dr. Chulay served as Senior Vice President and Chief Medical Officer at AlphaVax, where he led successful clinical trial programs of recombinant viral vector vaccines for cytomegalovirus and influenza. Dr. Chulay has also worked at GlaxoSmithKline as the Principal Clinical Program Head in HIV and Opportunistic Infections, responsible for bringing two anti-infective drugs to market; Walter Reed Army Medical Institute of Research (WRAIR) as Chief of the Department of Immunology; and U.S. Army Research Institute of Infectious Disease as Chief of the Virology Division. Dr. Chulay earned a medical degree from Northwestern University Medical School and a degree in tropical medicine and hygiene from the London School of Hygiene and Tropical Medicine. He served his residency at Cleveland Metropolitan General Hospital and was a fellow in Infectious Disease at WRAIR. He has been a member of the Institute of Medicine Committee on Prevention and Control of Malaria, published more than 100 papers in peer-reviewed journals and is a reviewer for several leading medical journals.
Since AGTC’s inception, Dr. Knop has been responsible for the development of all upstream and downstream unit operations comprising the company’s proprietary rHSV co-infection method for rAAV manufacture.
Dr. Knop joined AGTC in 2002 after completing his doctoral research in Chemical Engineering at Michigan State University which focused on biocatalytic production of value-added pharmaceutical intermediates useful in the synthesis of anti-influenza medicinals. He has defined, and executed technology transfer on, multiple phase 1 and 2 clinical material generation processes for rHSV raw material and rAAV clinical trial material to contract manufacturing organizations, academic and corporate partners. Dr. Knop has authored dozens of manuscripts, presentations, and posters encompassing the production, processing, and purification of rHSV and rAAV vectors for use in gene therapy applications.